Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8733 |
High Similarity |
NPD1653 |
Approved |
0.8601 |
High Similarity |
NPD5124 |
Phase 1 |
0.8601 |
High Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.8322 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.8291 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8242 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.8143 |
Intermediate Similarity |
NPD1091 |
Approved |
0.8061 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.8014 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.8 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.795 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7925 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7911 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7875 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7875 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7829 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7812 |
Intermediate Similarity |
NPD37 |
Approved |
0.7806 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7785 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7778 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7778 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7778 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7778 |
Intermediate Similarity |
NPD4965 |
Approved |
0.777 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7738 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7697 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7692 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7683 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7679 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7669 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7661 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.764 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7635 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7633 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7632 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.761 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7602 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7564 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7558 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7546 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7546 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7533 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD5402 |
Approved |
0.75 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7484 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7483 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7468 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7467 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7459 |
Intermediate Similarity |
NPD7583 |
Approved |
0.7452 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7452 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7452 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.745 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7434 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7423 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7421 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7419 |
Intermediate Similarity |
NPD7585 |
Approved |
0.7417 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7399 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7394 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7391 |
Intermediate Similarity |
NPD920 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7378 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7375 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7372 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7372 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7372 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7372 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7372 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7355 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7351 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7349 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7325 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7318 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7315 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7314 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7314 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7312 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7308 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7303 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7297 |
Intermediate Similarity |
NPD4749 |
Approved |
0.729 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.729 |
Intermediate Similarity |
NPD4536 |
Approved |
0.729 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7289 |
Intermediate Similarity |
NPD2415 |
Discontinued |
0.7289 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7273 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7267 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7261 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7257 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7256 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7251 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7251 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7251 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7251 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7244 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7241 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7232 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7219 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7219 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7211 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7202 |
Intermediate Similarity |
NPD3749 |
Approved |
0.72 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.719 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.719 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7183 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7584 |
Approved |
0.7168 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.716 |
Intermediate Similarity |
NPD919 |
Approved |
0.716 |
Intermediate Similarity |
NPD2533 |
Approved |
0.716 |
Intermediate Similarity |
NPD2532 |
Approved |
0.716 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7153 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7151 |
Intermediate Similarity |
NPD6843 |
Phase 3 |
0.7151 |
Intermediate Similarity |
NPD6842 |
Approved |
0.7151 |
Intermediate Similarity |
NPD6841 |
Approved |
0.7143 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7143 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7143 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7134 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7134 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7134 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.7126 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7126 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7117 |
Intermediate Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7091 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7089 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7089 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7076 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7075 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7071 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7071 |
Intermediate Similarity |
NPD290 |
Approved |
0.707 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7066 |
Intermediate Similarity |
NPD4433 |
Discontinued |
0.7063 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7055 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7037 |
Intermediate Similarity |
NPD6666 |
Approved |
0.7037 |
Intermediate Similarity |
NPD6667 |
Approved |
0.7035 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7035 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7035 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7019 |
Intermediate Similarity |
NPD7982 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7006 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6994 |
Remote Similarity |
NPD7213 |
Phase 3 |
0.6994 |
Remote Similarity |
NPD1511 |
Approved |
0.6994 |
Remote Similarity |
NPD7212 |
Phase 2 |
0.6988 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD8158 |
Clinical (unspecified phase) |
0.6977 |
Remote Similarity |
NPD6959 |
Discontinued |
0.6975 |
Remote Similarity |
NPD6190 |
Approved |
0.6968 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6959 |
Remote Similarity |
NPD1357 |
Approved |
0.6957 |
Remote Similarity |
NPD2800 |
Approved |
0.6951 |
Remote Similarity |
NPD7447 |
Phase 1 |
0.6948 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6943 |
Remote Similarity |
NPD1933 |
Approved |
0.6943 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6943 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6931 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6929 |
Remote Similarity |
NPD9697 |
Approved |
0.6928 |
Remote Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD6671 |
Approved |
0.6918 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6914 |
Remote Similarity |
NPD7473 |
Discontinued |
0.6909 |
Remote Similarity |
NPD1512 |
Approved |
0.6906 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6898 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.6887 |
Remote Similarity |
NPD9717 |
Approved |
0.6886 |
Remote Similarity |
NPD3226 |
Approved |
0.6882 |
Remote Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD1240 |
Approved |
0.6879 |
Remote Similarity |
NPD3134 |
Approved |
0.6879 |
Remote Similarity |
NPD4307 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD6100 |
Approved |
0.6875
|
Remote Similarity |
NPD969 |
Suspended |